Cancer Drugs And Medicare: Range Of Impacts Expected From IRA Price Reforms
Executive Summary
Alkermes discusses oncology drug spin-off, Lilly discloses decision to halt development of a small molecule drug, and AbbVie comments on pending Medicare price negotiation for Imbruvica.